

22 Kyorin University School of Medicine

23 6-20-2, Shinkawa, Mitaka, Tokyo, 181-8611, Japan

24 E-mail: kouki7@ks.kyorin-u.ac.jp

25 **Abstract:**

26 **Objective**

27 In Japan, healthcare workers (HCWs) are vaccinated against contagious viruses
28 (measles, rubella, chickenpox, mumps, and hepatitis B) to prevent nosocomial infection;
29 however, some do not produce sufficient antibodies (suboptimal responders). Whether
30 suboptimal responders to live attenuated viruses or inactivated viruses vaccines can
31 produce adequate antibodies to severe acute respiratory syndrome coronavirus 2
32 (SARS-CoV-2) mRNA vaccines remains to be elucidated.

33 **Methods**

34 In this prospective cohort study, SARS-CoV-2 anti-spike antibodies were
35 measured 11 times, from before the first BNT162b2 vaccination to 5 months after the
36 second vaccination. Antibody titers of suboptimal and normal responders were
37 compared. SARS-CoV-2 neutralizing antibody activity was measured twice in
38 suboptimal responders, 1 week to 1 month, and 5 months after the second vaccination.

39 **Patients**

40 This study included 50 HCWs who received two doses of mRNA BNT162b2
41 vaccine 3 weeks apart.

42 **Results**

43 After vaccination, the SARS-CoV-2 anti-spike antibody was detectable in the
44 samples from suboptimal and normal responders at each timepoint. The median SARS-
45 CoV-2 anti-spike antibody titer was higher in suboptimal responders than in normal
46 responders 1 week after receiving the second dose of BNT162b2 vaccine (3721.0 vs.
47 2251.5, $P=0.029$). Suboptimal responders had SARS-CoV-2 neutralizing antibody

48 activity 1 week to 1 month, and 5 months after the second vaccination, which exceeded
49 the positive threshold 5 months after the second vaccination.

50 **Conclusion**

51 After BNT162b2 vaccination, suboptimal responders acquired adequate SARS-
52 CoV-2 anti-spike and SARS-CoV-2 neutralizing antibodies to prevent SARS-CoV-2.
53 These results suggest that vaccination with mRNA vaccine against SARS-CoV-2 should
54 also be recommended for suboptimal responders to conventional vaccines.

55

56 **Keywords:**

57 coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus 2
58 (SARS-CoV-2), mRNA vaccine, anti-spike antibody, neutralizing antibody

59

60 **Introduction**

61 Coronavirus disease (COVID-19), which is caused by severe acute respiratory
62 syndrome coronavirus 2 (SARS-CoV-2), has been declared a pandemic (1-4). In view of
63 the high number of cases of severe illness and death due to COVID-19, vaccination
64 against SARS-CoV-2 infection is crucial.

65 SARS-CoV-2 has an enveloped, single, positive-stranded RNA genome that
66 encodes four major viral structural proteins, namely, the nucleocapsid, spike, envelope,
67 and membrane proteins; the latter three proteins are found in its membrane. The spike
68 protein guides viral entry into host cells by binding to angiotensin-converting enzyme 2
69 (ACE2) receptors, which are widely expressed on epithelial cells and macrophages (5-7)
70 and is thus an ideal target for messenger RNA (mRNA) vaccine development.

71 The BNT162b2 mRNA vaccine (Pfizer–BioNTech) is highly effective at
72 preventing clinically significant COVID-19 (8-10), reducing the incidence of
73 asymptomatic infection and associated infectivity (11,12), and preventing the spread of
74 COVID-19 (9). The BNT162b2 vaccine was the first SARS-CoV-2 vaccine to be
75 approved in Japan, and priority vaccination of healthcare workers (HCWs) began in
76 February 2021 in order to safeguard the medical delivery system (13).

77 HCWs also have a high risk of infection with other contagious viruses such as
78 measles, rubella, chickenpox, mumps, and hepatitis B. Therefore, in Japan, HCWs are
79 vaccinated against these viruses to prevent nosocomial infections and viral antibody
80 titers are measured to ensure the presence of protective antibody levels (14). However,
81 some individuals do not develop adequate antibody titers against contagious viruses
82 even after vaccination. Such individuals are called suboptimal responders. It is unclear

83 whether suboptimal responders to conventional vaccines can produce adequate SARS-
84 CoV-2 antibodies, including neutralizing antibodies, after vaccination with the
85 BNT162b2 vaccine to protect them against SARS-CoV-2 infection. Therefore, in this
86 study, we investigated whether suboptimal responders acquired SARS-CoV-2 anti-spike
87 and SARS-CoV-2 neutralizing antibodies after vaccination with the BNT162b2 vaccine.

88

89 **Materials and methods**

90

91 ***Participants***

92 The study was conducted at Kyorin University Hospital in Tokyo, Japan.
93 HCWs at the hospital received two doses of the BNT162b2 vaccine 3 weeks apart. The
94 participants were HCWs at the hospital who agreed to participate in the study and to
95 periodically donate blood samples before and after vaccination. Those whose antibody
96 levels were below the standard values for preventing infection after receiving two or
97 more doses of vaccine against measles, rubella, chickenpox, mumps, or hepatitis B
98 viruses were classified as suboptimal responders.

99

100 ***SARS-CoV-2 anti-spike antibody assay***

101 SARS-CoV-2 anti-spike antibody measurements were performed on serum
102 obtained from centrifuged peripheral blood using the Elecsys Anti-SARS-CoV-2 S RUO
103 (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) on a Cobas 6000 (Roche
104 Diagnostics) analyzer via the double-antigen sandwich enzyme-linked immunoassay
105 method (15). Samples were collected before the first dose of BNT162b2 vaccine was

106 administered; 3 days after the first vaccination; 1, 2, and 3 weeks after the first
107 vaccination; 1 week after the second vaccination; and 1, 2, 3, 4, and 5 months after the
108 second vaccination. The measurement range of the antibody assay was 0.4–250, and
109 samples with an antibody titer of ≥ 250 U/mL were assayed again after dilution.

110

111 ***SARS-CoV-2 neutralizing antibody assay***

112 Using serum obtained from the peripheral blood of suboptimal responders after
113 vaccination, SARS-CoV-2 neutralizing antibody activity was measured at Osaka
114 University Microbial Disease Research Association Laboratory. A 50% inhibitory
115 dilution factor (ID₅₀) using pseudovirus (16) was measured, and ID₅₀ values of ≥ 50 was
116 considered positive (17). For the neutralization assay, 60 μ L of pseudovirus, which is
117 equivalent to 2.5×10^6 relative light units (RLU)/mL, was incubated with 60 μ L of serial
118 dilutions of serum samples for 1 h at 37°C. After incubation, 100 μ L of the mixture was
119 added to the Vero cells in a 96-well plate. The cells were lysed 24 h post-infection,
120 luciferase was activated using the Luciferase Assay System (E1501, Promega,
121 Wisconsin, USA), and RLU were measured using a Synergy LX analyzer (BioTek,
122 USA). Percent neutralization was calculated using GraphPad Prism 8.0.2 (GraphPad
123 Software, San Diego, California, USA). Percentages of RLU reduction (inhibition rate)
124 were calculated as follows: $1 - (\text{RLU of sample sera} - \text{pseudovirus only wells}) / (\text{RLU}$
125 $\text{from medium only wells} - \text{pseudovirus only wells}) \times 100\%$. The titers of neutralizing
126 sera were calculated as ID₅₀. The transition of neutralizing antibody activity values after
127 vaccination in suboptimal responders was examined 1 week to 1 month and 5 months
128 after receiving the second dose of the BNT162b2 vaccine.

129

130 *Statistical analysis*

131 Nonparametric continuous data are reported as median and interquartile range
132 (IQR). The Mann–Whitney U test was performed to assess whether differences between
133 cohorts were statistically significant. Two-sided *P*-values of <0.05 were considered
134 statistically significant. The Wilcoxon matched-pairs signed rank test was performed to
135 assess whether differences in antibody levels within an individual at different time
136 points were statistically significant. To compare the age (ratio of the number of
137 individuals aged 20–40 years and those aged 50–60 years) and sex compositions of the
138 suboptimal responders and normal responders, Fisher’s exact test was performed to test
139 the statistical significance. The Mann–Whitney U test was performed to test for
140 statistically significant differences in antibody levels between suboptimal responders
141 and normal responders 1 week after the second vaccination. All statistical analyses were
142 performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama,
143 Japan), which is a graphical user interface for R (The R Foundation for Statistical
144 Computing, Vienna, Austria) (18). Specifically, EZR is a modified version of R
145 commander (version 1.54) that has been designed to add statistical functions frequently
146 used in biostatistics.

147

148 **Results**

149 The suboptimal responders comprised three men (L1, L2, L4) with negative
150 (titer <16.0) anti-measles immunoglobulin G (IgG) antibody titer after measles virus
151 vaccination and one woman (L3) with a negative (titer <4.0) anti-mumps IgG antibody

152 titer after mumps virus vaccination. Forty-six participants, comprising 12 men and 34
153 women, had antiviral antibody titers after vaccination against other viruses above the
154 standard value (normal responders). The four suboptimal responders were aged 20–40
155 years. Normal responders were older than suboptimal responders (the ratios of the
156 number of those aged 50–60 years were 57% vs. 0%, respectively), but no significant
157 difference was observed ($P > 0.99$). In addition, the male/female ratio was higher in
158 suboptimal responders than in normal responders (74% vs. 15%), but no significant
159 difference was observed ($P > 0.99$). All suboptimal responders were non-smokers and
160 non-obese, and none of them had a history of immunosuppressive drug use or having a
161 medical condition associated with immunodeficiency.

162

163 ***SARS-CoV-2 anti-spike antibody levels***

164 The median (IQR) SARS-CoV-2 anti-spike antibody titer was 2251.5 (1639.0–
165 3276.3) in the normal responders and 3721.0 (3255.0–4983.3) in the suboptimal
166 responders 1 week after receiving the second dose of BNT162b2 vaccine. This
167 difference was statistically significant ($P=0.029$) (Fig. 1A). For the total antibody level
168 1 week after the second vaccination, there was no significant difference in the median
169 antibody levels between those aged 50–60 years and those aged 20–40 years ($P=0.66$).

170 The median (IQR) SARS-CoV-2 anti-spike antibody in normal responders was
171 2251.5 (1639.0–3276.3) and 779.3 (534.6–1024.3) measured 1 week and 5 months,
172 respectively, after receiving the second dose of BNT162b2 vaccine (Fig. 1B). In
173 suboptimal responders, the median (IQR) SARS-CoV-2 anti-spike antibody titers were

174 3721.0 (3255.0–4983.3) and 666.7 (578.9–880.6) measured 1 week and 5 months,
175 respectively, after receiving the second dose of BNT162b2 vaccine (Fig. 1C).
176 SARS-CoV-2 anti-spike antibody was produced by both suboptimal and normal
177 responders, but the level was lower at 5 months than at 1 week after the second dose of
178 vaccine (Fig. 1).
179

180 (A) SARS-CoV-2 anti-spike antibody responses over the whole study period from
181 before the first dose to 5 months after the second dose of vaccine.

182 (B) SARS-CoV-2 anti-spike antibody titers in normal responders 1 week and 5 months
183 after receiving the second dose of the BNT162b2 vaccine. The antibody titers were
184 significantly lower at 5 months than at 1 week after the second dose ($P<0.001$).

185 (C) SARS-CoV-2 anti-spike antibody titers in suboptimal responders 1 week and 5
186 months after receiving the second dose of the BNT162b2 vaccine. The antibody titers
187 decreased, but the decrease was not statistically significant ($P=0.068$).

188 The box plot comparisons were performed using the Mann–Whitney U test. P -values
189 <0.05 were considered statistically significant. Suboptimal responders had low-level
190 antibody responses to previous measles or mumps vaccines, and normal responders had
191 normal antibody responses to previous antiviral vaccines.

192 NaN; not a number

193

194 ***SARS-CoV-2 neutralizing antibody activity in participants with***
195 ***suboptimal antibody responses to previous antiviral vaccines***

196 SARS-CoV-2 neutralizing antibody titers were 1154.0 in L1 at 1 week after
197 receiving the second dose of BNT162b2 vaccine and 774.2, 638.3, and 654.6 in L2, L3,
198 and L4, respectively, at 1 month after receiving the second dose of BNT162b2 vaccine
199 (Fig. 2). In the 5 months after the second vaccination, SARS-CoV-2 neutralizing
200 antibody titers were 105.5, 147.7, 485.2, and 894.4 in L1, L2, L3, and L4, respectively
201 (Fig. 2). All four suboptimal responders had a neutralizing antibody activity within the
202 protective range (≥ 50), from the 1 week to 1 month and 5 months after the second

203 vaccination (Fig. 2). The SARS-CoV-2 neutralizing antibody level in suboptimal
204 responders was lower at 5 months after receiving the second dose of BNT162b2 vaccine
205 than at 1 week to 1 month after receiving the second dose, but this difference was not
206 statistically significant ($P=0.38$) (Fig. 2).

207

208 Data are presented as 50% inhibitory dilutions (ID_{50}). The dashed line indicates the
209 cutoff for ID_{50} (17).

210

211 **Discussion**

212 The BNT162b2 vaccine has been highly effective in preventing clinically
213 significant COVID-19 (8-10). However, limited information is available about the
214 effectiveness of the BNT162b2 vaccine in suboptimal responders to conventional
215 vaccines. In this study, suboptimal responders produced adequate SARS-CoV-2 anti-
216 spike antibodies and neutralizing antibodies.

217 Muik et al. (19) measured the neutralization efficacy of sera from 40 healthy
218 German individuals immunized with the BNT162b2 vaccine and a 50% inhibitory
219 dilution factor using pseudovirus according to the same method as was used in this
220 study. The SARS-CoV-2 neutralizing activity of the suboptimal responders in this study
221 1 week to 1 month after receiving the second dose of BNT162b2 vaccine was
222 comparable to that of the participants in the German study. All four suboptimal
223 responders developed protective levels of neutralizing antibodies. The SARS-CoV-2
224 neutralizing antibody activity value in the fifth month after the second dose of
225 BNT162b2 vaccine did not show a significant decrease in activity compared with that 1
226 week to 1 month after receiving the second dose of BNT162b2 vaccine. The SARS-

227 CoV-2 anti-spike antibody titer was lower at 5 months after the second dose of
228 BNT162b2 vaccine than at 1 week after the second dose, but the decrease was not
229 statistically significant in suboptimal responders. These results suggest that mRNA
230 vaccines can invoke a protective immune response even in suboptimal responders who
231 do not develop adequate antibody titers against viruses in response to conventional
232 vaccines against viral diseases such as mumps and measles.

233 Measles, rubella, chickenpox, and mumps vaccines are live attenuated vaccines
234 that weaken the toxicity of pathogenic microorganisms, and hepatitis B vaccines are
235 inactivated vaccines that cause pathogenic microorganisms to lose their ability to infect
236 (20). In previous studies, approximately 2–10% of healthy individuals do not produce
237 protective antibody levels in response to viral vaccines (21). The risk factors for low
238 response to these conventional viral vaccines include male sex, age of >40 years,
239 smoking habit, obesity, chronic diseases, and genetic factors. However, the factors
240 associated with a low antibody response to SARS-CoV-2 mRNA vaccines are not well
241 understood. Smokers, patients with cancer and hematological malignancies, and organ
242 transplant recipients have been reported to have a lower SARS-CoV-2 anti-spike
243 antibody response than individuals without these characteristics after receiving SARS-
244 CoV-2 vaccines (22-26). It is intriguing that the suboptimal responders in this study who
245 did not produce adequate antibodies against measles or mumps produced adequate
246 SARS-CoV-2 anti-spike antibodies after receiving the BNT162b2 vaccine. They were
247 healthy and did not have risk factors such as an organ transplant and
248 immunosuppression. One possible reason for this discrepancy is the different

249 mechanism of antibody production between conventional vaccines and SARS-CoV-2
250 mRNA vaccines.

251 The BNT162b2 vaccine is an mRNA vaccine that incorporates mRNA
252 encoding spike protein (antigen) on the surface of the SARS-CoV-2 into human cells.
253 The produced antigen directly functions as a template to induce the acquired immune
254 system (27). On the other hand, with live attenuated vaccines or inactivated vaccines, it
255 is necessary for recipients to process the vaccine and recognize it as an antigen. The
256 difference in the mechanism of action of vaccines could be a factor contributing to the
257 discrepancy in response to the BNT162b2 vaccine from the response to conventional
258 live attenuated vaccines among suboptimal responders. Such a hypothesis should be
259 tested in future studies. It is also unclear why suboptimal responders had higher
260 antibody titers than normal responders in the first week after the second dose of vaccine.

261 Of note, the SARS-CoV-2 anti-spike antibody level is known to peak and then
262 decrease within months after the second vaccination, which is a much shorter period
263 than that of antibodies against live attenuated vaccines (28,29). In order to achieve
264 adequate COVID-19 disease control, a third dose of SARS-CoV-2 mRNA vaccine is
265 needed, which is already being administered in many countries. In view of the results of
266 the present study, a third dose of the BNT162b2 vaccine is recommended for both
267 suboptimal and normal responders to conventional vaccines. (28)

268 This study has some limitations. The number of participants was limited, and
269 all participants were HCWs vaccinated at a single hospital. In addition, there were no
270 suboptimal responders to inactivated vaccines (such as hepatitis B) included in this

271 study. Multicenter studies with a larger sample size are needed to confirm the results of
272 the present study. In addition, further immunological studies are necessary to clarify the
273 mechanism by which humoral immunity is acquired after mRNA vaccination in
274 suboptimal responders to conventional vaccines.

275 In conclusion, after two doses of the BNT162b2 vaccine, suboptimal
276 responders to conventional antiviral vaccines developed protective levels of SARS-
277 CoV-2 anti-spike and SARS-CoV-2 neutralizing antibodies. These results suggest that
278 vaccination with mRNA vaccine against SARS-CoV-2 should also be recommended to
279 suboptimal responders against conventional vaccines.

280

281 **Ethics consideration**

282 We carried out a prospective cohort study of 50 HCWs. This study was
283 conducted with the approval of the Ethics Committee of Kyorin University School of
284 Medicine (Number R02-041), and was in accordance with the Declaration of Helsinki.
285 Informed consent was obtained from all study participants.

286

287 **Acknowledgments**

288 We thank the HCWs of the Department of Clinical Laboratory, Kyorin
289 University Hospital involved in the SARS-CoV-2 antibody monitoring for their valuable
290 contribution.

291

292 **References**

- 293 1. Coronaviridae Study Group of the International Committee on Taxonomy of
294 Viruses, Baker SC, Baric RS, et al. The species severe acute respiratory
295 syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-
296 2. *Nat Microbiol* 5:536-544, 2020.
- 297 2. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory
298 disease in China. *Nature* 579:265-269, 2020.
- 299 3. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new
300 coronavirus of probable bat origin. *Nature* 579:270-273, 2020.
- 301 4. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with
302 pneumonia in China, 2019. *N Engl J Med* 382:727-733, 2020.
- 303 5. Song Z, Xu Y, Bao L, et al. From SARS to MERS, Thrusting coronaviruses into
304 the spotlight. *Viruses* 11:59, 2019.
- 305 6. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry
306 depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease
307 inhibitor. *Cell* 181:271-280.e8, 2020.
- 308 7. Jiang S, Lu L, Liu Q, Xu W, Du L. Receptor-binding domains of spike proteins of
309 emerging or re-emerging viruses as targets for development of antiviral vaccines.
310 *Emerg Microbes Infect* 1:e13, 2012.
- 311 8. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA
312 BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases,
313 hospitalisations, and deaths following a nationwide vaccination campaign in
314 Israel: an observational study using national surveillance data. *Lancet* 397:1819-
315 1829, 2021.

- 316 9. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2
317 mRNA Covid-19 vaccine. *N Engl J Med* 383:2603-2615, 2020.
- 318 10. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a
319 nationwide mass vaccination setting. *N Engl J Med* 384:1412-1423, 2021.
- 320 11. Regev-Yochay G, Amit S, Bergwerk M, et al. Decreased infectivity following
321 BNT162b2 vaccination: a prospective cohort study in Israel. *Lancet Reg Health*
322 *Eur* 7:100150, 2021.
- 323 12. Petter E, Mor O, Zuckerman N, et al. Initial real world evidence for lower viral
324 load of individuals who have been vaccinated by BNT162b2. Preprint; 2021.
- 325 13. Pharmaceuticals and Medical Devices Agency. Special Approval for Emergency
326 on first COVID-19 vaccine in Japan [media release]. 2021. Available from:
327 [pmda.go.jp](https://www.pmda.go.jp/english/about-pmda/0003.pdf). [Cited 2022 February 20] Available from:
328 <https://www.pmda.go.jp/english/about-pmda/0003.pdf>
- 329 14. Kumakura S, Shibata H, Onoda K, Nishimura N, Matsuda C, Hirose M.
330 Seroprevalence survey on measles, mumps, rubella and varicella antibodies in
331 healthcare workers in Japan: sex, age, occupational-related differences and
332 vaccine efficacy. *Epidemiol Infect.* Cambridge University Press 142:12-19, 2014.
- 333 15. Riestler E, Findeisen P, Hegel JK, et al. Performance evaluation of the Roche
334 Elecsys anti-SARS-CoV-2 S immunoassay. *J Virol Methods* 297:114271, 2021.
- 335 16. Nie J, Li Q, Wu J, et al. Quantification of SARS-CoV-2 neutralizing antibody by a
336 pseudotyped virus-based assay. *Nat Protoc* 15:3699-3715, 2020.
- 337 17. McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-
338 CoV-2 in rhesus macaques. *Nature* 590:630-634, 2021.

- 339 18. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for
340 medical statistics. *Bone Marrow Transplant* 48:452-458, 2013.
- 341 19. Muik A, Wallisch AK, Sanger B, et al. Neutralization of SARS-CoV-2 lineage
342 B.1.1.7 Pseudovirus by BNT162b2 vaccine-elicited human sera. *Science*
343 371:1152-1153, 2021.
- 344 20. Krammer F. SARS-CoV-2 vaccines in development. *Nature* 586:516-527, 2020.
- 345 21. Wiedermann U, Garner-Spitzer E, Wagner A. Primary vaccine failure to routine
346 vaccines: why and what to do? *Hum Vaccin Immunother* 12:239-243, 2016.
- 347 22. Shem-Tov N, Yerushalmi R, Danylesko I, et al. Immunogenicity and safety of the
348 BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation
349 recipients. *Br J Haematol* 196:884-891, 2022.
- 350 23. Nomura Y, Sawahata M, Nakamura Y, et al. Age and smoking predict antibody
351 titres at 3 months after the second dose of the BNT162b2 COVID-19 vaccine.
352 *Vaccines (Basel)* 9:1042, 2021.
- 353 24. Herzog Tzarfati K, Gutwein O, Apel A, et al. BNT162b2 COVID-19 vaccine is
354 significantly less effective in patients with hematologic malignancies. *Am J*
355 *Hematol* 96:1195-1203, 2021.
- 356 25. Monin L, Laing AG, Munoz-Ruiz M, et al. Safety and immunogenicity of one
357 versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer:
358 interim analysis of a prospective observational study. *Lancet Oncol* 22:765-778,
359 2021.
- 360 26. Shroff RT, Chalasani P, Wei R, et al. Immune responses to two and three doses of
361 the BNT162b2 mRNA vaccine in adults with solid tumors. *Nat Med* 27:2002-
362 2011, 2021.

- 363 27. Mascellino MT, Di Timoteo F, De Angelis M, Oliva A. Overview of the main anti-
364 SARS-CoV-2 vaccines: mechanism of action, efficacy and safety. *Infect Drug*
365 *Resist* 14:3459-3476, 2021.
- 366 28. Israel A, Merzon E, Schäffer AA, et al. Elapsed time since BNT162b2 vaccine and
367 risk of SARS-CoV-2 infection: test negative design study. *BMJ* 375 :e067873,
368 2021.
- 369 29. Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to
370 BNT162b2 Covid-19 vaccine over 6 months. *N Engl J Med* 385:e84-e84, 2021.
- 371

372 **Figure legends**

373 **Fig 1. SARS-CoV-2 anti-spike antibody responses in suboptimal/normal**

374 **responders before and after vaccination with the BNT162b2 vaccine**

375

376 **Fig 2. SARS-CoV-2 neutralizing antibody activity responses after the second dose**

377 **of BNT162b2 vaccine in suboptimal responders**

Fig. 1A




Fig. 1B




Fig. 1C




Fig. 2

